Dyne Therapeutics Presents Preclinical Data from its Duchenne Muscular Dystrophy Programs Targeting…
- Poster Highlights In Vivo Data for DYNE-251, Now Being Evaluated in Phase 1/2 DELIVER Clinical Trial in Patients Amenable to Exon 51 Skipping - - First Presentation of In Vitro Data for FORCE™ Platform Conjugate Targeting Exon 53 -…